Yes. Prolonged culture can change how stem cells grow and function, not just how many cells are available. In studies of human bone marrow-derived mesenchymal stromal cells (MSCs), extensive expansion produced slow-dividing, senescent cells with increased aging markers and weaker responses to damage. In one laboratory comparison, the concentrations reducing measured viability by half (IC50) were 200 versus 400 μM for hydrogen peroxide and 13 versus 90 μg/ml for bleomycin in senescent versus early-passage cells. These are laboratory stress tests, not treatment doses or patient outcomes. PMC6036081
That does not mean all cultured cells are unusable. One university-hospital bank used four-week, low-passage cultures averaging 886 million cells each, with batches tested against release criteria. PMC4875672 There is no universal number of days or passages that makes a batch acceptable. Culture history and tests appropriate to the intended use matter more than the cell count alone.

What extended culture means for stem cells
Cell culture means keeping cells alive and growing outside the body in a nutrient liquid. When the dish gets crowded, technicians move some cells into a fresh vessel. Each move is called a passage or subculture.
Laboratories expand cells to increase the number available from a starting sample. After extensive expansion, MSCs can enter replicative senescence and barely multiply. PMC6036081 A culture-method study describes enlargement and a more granular appearance during cellular aging, citing 20–50 population doublings as general background for cultured human somatic cells. MSC aging depends on the culture conditions. PMC2878782
“Extended” means prolonged expansion here, not necessarily expansion beyond a laboratory’s validated limit. There is no universal cutoff. A passage is not a population doubling: one transfer can involve several doublings, depending on the culture method. The 20–50 doubling range above is background for cultured human somatic cells, not a clinical release limit or a universal MSC lifespan. Different MSC protocols can produce very different amounts of expansion within the same number of passages. PMC2878782
Why culture time matters when comparing offers
Two vials can hold equal numbers but have different biological properties. Living cells can be senescent, so a viability count does not measure all the changes that occur during expansion. PMC6036081
The FDA warns that unapproved regenerative medicine products can carry serious risks, including infection and unwanted tissue growth. A large cell count is not evidence that an intervention is safe or effective. Important patient and consumer information about regenerative medicine therapies In Japan, a provision plan is submitted under the Act on the Safety of Regenerative Medicine, with committee review requirements. Filing that plan is not, by itself, proof of clinical benefit or a medicinal product approval. En
What changes in stem cells during long expansion
The laboratory studies discussed here concern human bone marrow-derived MSCs, often called “mesenchymal stem cells.” They describe cell properties, not whether a treatment helps a disease, and should not be generalized to every stem cell type.
| What changes | What researchers observe | Why it matters |
|---|---|---|
| Growth speed | Proliferation slows; senescent cells barely multiply PMC6036081 | A batch may never reach the needed dose in a workable time |
| Cell shape and size | Cells can enlarge and become more granular during culture aging PMC2878782 | Morphology is one observation, not a universal release criterion |
| Aging signals | Higher senescence-associated beta-galactosidase activity and higher levels of the P53 and P16 pathways PMC6036081 | These are laboratory markers of cell aging, not a diagnosis |
| Differentiation | Senescence can affect differentiation potential, but studied preparations also retained differentiation capacity while acquiring gene-expression changes PMC2878782 | The ISCT criteria describe laboratory differentiation into bone, fat, and cartilage cells; a gene-expression change alone does not prove its loss 16923606 |
| Identity markers | MSC preparations retained their characteristic immunophenotype despite senescence-associated gene-expression changes PMC2878782 | An identity panel does not establish that cells are free of aging-related changes |
| Damage responses | Senescent cells show weaker DNA damage responses and reduced anti-oxidative capacity PMC6036081 | Routine release tests do not necessarily measure these vulnerabilities |
They slow down and age
In a laboratory study using bone marrow MSCs from three healthy volunteers, long-term culture produced senescent cells that remained alive but divided poorly, with increased senescence-associated beta-galactosidase activity and p53/p16 expression. PMC6036081 The concentrations reducing measured cell viability by half (IC50) were 200 versus 400 μM for hydrogen peroxide and 13 versus 90 μg/ml for bleomycin in senescent versus early-passage cells. The latter is roughly one-seventh the concentration, not one-seventh the patient risk. PMC6036081 Expression of antioxidant genes Cu/Zn-SOD, GPX, and CAT was roughly halved (P<0.05). Damage markers that returned toward baseline within about 12 hours in early-passage cells remained elevated at 24 hours in senescent cells. PMC6036081
Senescence reflects normal cell biology rather than contamination, and it does not convert cells into another cell type. Even so, a vial of vigorous cells and a vial of senescent ones can share the same label count.
Differentiation needs its own assessment
The 2006 ISCT criteria describe MSC identity through plastic adherence, a surface-marker profile, and differentiation into bone, fat, and cartilage cells under laboratory conditions. 16923606 The culture-method study discusses impaired differentiation with senescence, but also reports preparations that retained their differentiation capacity while acquiring gene-expression changes. It does not establish that every extended culture loses all three abilities. PMC2878782
Identity markers can miss aging-related changes
The ISCT profile requires at least 95% of cells to express CD105, CD73, and CD90, and no more than 2% to express the specified negative markers: CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR. These are characterization criteria, not a universal clinical release specification or a test of treatment effectiveness. 16923606
In the culture-method comparison, MSC preparations showed senescence-associated gene-expression changes despite retaining their characteristic immunophenotype. A satisfactory surface-marker result cannot substitute for assessing growth history and other relevant cell properties. PMC2878782
Damage handling gets weaker
Cells accumulate stress when they divide again and again in the artificial environment of a dish. Compared with earlier-passage cells, replicative senescent MSCs show defects in DNA damage responses and reduced anti-oxidative capacity PMC6036081. This laboratory finding concerns cell quality. It does not support claims about cancer risk or treatment outcomes in people.
What extended culture does not automatically mean
Neither short nor long culture proves safety. Senescence, contamination, identity, and viability are different questions; a result for one cannot settle the others. Passing routine release tests does not prove that a batch has no aging-related changes. The culture-method study specifically argues for monitoring replicative senescence as part of quality control. PMC2878782
A low passage number is useful only alongside the process details. Different protocols can produce very different numbers of population doublings per passage, so “low passage” is not a universal quality grade. PMC2878782
How careful laboratories limit and test culture time
Ask how the laboratory controls expansion and decides whether a batch is suitable for its intended use. The Belgian bank provides a documented example, not a rule that every provider uses the same process.
- Culture limits and history. Request the passage number, cumulative population doublings if available, culture duration, and the validated expansion limit.
- Batch testing. Ask the processing facility for the actual specification and results for identity, viability, and contamination testing. Ask separately how growth performance or senescence is assessed.
- Traceable records. Check that the tissue source, culture history, test results, and intended final container refer to the same batch.
- Failed batches. Ask for the policy on withholding batches that do not meet specifications, including those outside the validated process.
- A published example of short, low-passage expansion. One Belgian university-hospital bank (activity reported 2007 through June 2015) completed 68 clinical-grade large-scale MSC cultures from 59 validated donors, expanding each for 4 weeks to a mean yield of 886 million cells per culture and storing 464 frozen aliquots (mean 132.8 million cells per bag); 314 bags were later released across 6 clinical protocols, every thawed unit met release criteria, and no infusion-related toxicity was reported PMC4875672. This record describes manufacturing. It does not prove that any treatment works.
The bank’s report is a historical manufacturing and infusion record, not a comparison proving treatment efficacy or the absence of all possible harms. Its four-week expansion is not a universal safe time limit.
What to ask before paying
When comparing providers in Japan, request written answers that identify the cells and the evidence, not just the advertised dose.
- What cells are these — type, tissue source, and donor source (my own or a donor’s)?
- Were the cells expanded in culture? What are the culture duration, passage number, and population doublings, and how do they compare with the validated process?
- Which identity, viability, contamination, and relevant functional tests are performed? How is senescence assessed, if at all?
- What happens to batches that fail — are they ever used?
- Is this a product approval, a supervised provision plan, or a clinical trial — and what is the exact indication?
- What human evidence matches my diagnosis, cell product, and administration route? Ask about patient numbers, a comparison group, measured outcomes, follow-up, and adverse events.
If a reply gives only a cell count and “95% viability,” it still leaves the culture question unanswered. Request the passage history and batch-specific release record, then check that their batch identifiers match. If preparation has not yet occurred, ask when those records will be available. This is a document-checking scenario, not a patient case or a method for independently certifying a batch’s safety.
Have these six answers from a clinic and unsure what they show?
Send the passage number, release tests, and regulatory route. Support staff can review what is documented before you commit to travel.
The bottom line
Extended culture can change MSC growth, aging markers, gene expression, and stress responses. In one laboratory comparison, the hydrogen peroxide IC50 was 200 μM in senescent cells versus 400 μM in early-passage cells. PMC6036081 Controlled expansion is still possible: the Belgian bank’s four-week, low-passage process is one documented example, not a universal safe time limit. PMC4875672 Ask for culture history and batch-specific testing; neither a cell count nor an identity panel answers every quality question.
Cell-quality findings and evidence of patient benefit answer different questions. Both matter when assessing a proposed treatment.
Approval is product- and indication-specific. On December 18, 2024, the FDA approved Ryoncil, a donor bone marrow-derived MSC therapy, for steroid-refractory acute graft-versus-host disease in children aged two months and older. Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host That approval does not establish that another MSC preparation works for another condition.
General information for adults, not personal medical advice. Laboratory findings described here concern cells in culture and do not predict individual treatment results.




